Association between Metabolic Syndrome and Its Components with Cardiovascular Disease Risk in the MASHAD Cohort Study Population

Document Type : Original Article

Authors

1 Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

2 International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Department of Biology, Faculty of Basic Sciences, Hakim Sabzevari University, P.O.Box:397, Sabzevar, Iran.

5 Department of Biostatistics and Epidemiology, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.

6 Department of Nutrition Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran.

7 Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.

8 Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

9 Department of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.

10 Norwegian Center for E-Health Research, University Hospital of North Norway, Tromsø, Norway.

11 Cardiovascular Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

12 Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK.

13 Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Introduction: The primary aim of this study was to evaluate the association of metabolic syndrome (MetS), based on different definitions, with the risk of total cardiovascular disease (CVD), unstable angina (UA), stable angina (SA), and myocardial infarction (MI). Additionally, we aimed to investigate which definition of MetS is a better predictor of CVD events in a large sample of Iranian adults.
Methods: The analysis was conducted among 7,910 adults from the Mashhad Stroke and Heart Atherosclerotic Disorder (MASHAD) cohort study. The presence of MetS at baseline was defined using the following criteria: International Diabetes Federation (IDF 2005), National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), and World Health Organization (WHO). Hazard ratios (HR) and 95% confidence intervals (CI) were used to estimate the association of MetS and its components with CVD events.
Results: The prevalence of MetS among CVD patients was 56.40%, 52.30%, and 23.90% based on the IDF, NCEP ATP III, and WHO criteria, respectively. The highest HR for total CVD (HR: 2.29; 95% CI: 1.54–3.40; P<0.001), UA (HR: 2.13; 95% CI: 1.22 – 3.72; P<0.01), and MI (HR: 3.11; 95% CI: 1.33–7.26; P<0.01) was found when using the WHO definition. The highest HR for SA (HR: 2.56; 95% CI: 1.37 – 4.81; P<0.001) was found when using the NCEP ATP III definition.
Conclusion: Having MetS based on the WHO definition was a significant predictor for the incidence of total CVD, MI, and UA, while having MetS based on the ATP III criteria was associated with a higher risk of SA in the MASHAD study population.

Keywords

References

  1. Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. European heart journal. 2007 Apr 1;28(7):857-64.
  2. Alberti G, Zimmet P, Shaw J, Grundy SM. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: International Diabetes Federation. 2006 May;23(5):469-80.
  3. Maria A. Expert panel on detection e, treatment of high blood cholesterol in A. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486-97.
  4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic medicine. 1998 Jul;15(7):539-53.
  5. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world‐wide definition. A consensus statement from the international diabetes federation. Diabetic medicine. 2006 May;23(5):469-80.
  6. Parsamanesh N, Karami-Zarandi M, Banach M, Penson PE, Sahebkar A. Effects of statins on myocarditis: a review of underlying molecular mechanisms. Progress in cardiovascular diseases. 2021 Jul 1;67:53-64.
  7. Delavari A, Forouzanfar MH, Alikhani S, Sharifian A, Kelishadi R. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes care. 2009 Jun 1;32(6):1092-7.
  8. Hadaegh F, Zabetian A, Tohidi M, Ghasemi A, Sheikholeslami F, Azizi F. Prevalence of metabolic syndrome by the Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions and their association with coronary heart disease in an elderly Iranian population. Annals Academy of Medicine Singapore. 2009 Feb 1;38(2):142.
  9. Amirkalali B, Fakhrzadeh H, Sharifi F, Kelishadi R, Zamani F, Asayesh H, et al. Prevalence of metabolic syndrome and its components in the Iranian adult population: a systematic review and meta-analysis. Iranian red crescent medical journal. 2015 Dec 27;17(12):e24723.
  10. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes research and clinical practice. 2003 Jul 1;61(1):29-37.
  11. Tayefi M, Saberi-Karimian M, Esmaeili H, Zadeh AA, Ebrahimi M, Mohebati M, et al. Evaluating of associated risk factors of metabolic syndrome by using decision tree. Comparative clinical pathology. 2018 Jan;27:215-23.
  12. Sadeghi M, Haghdoost AA, Bahrampour A, Dehghani M. Modeling the burden of cardiovascular diseases in Iran from 2005 to 2025: the impact of demographic changes. Iranian journal of public health. 2017 Apr;46(4):506.
  13. Aghasizadeh M, Bizhaem SK, Baniasadi M, Khazdair MR, Kazemi T. Evaluation of LDL goal achievement in statin consumption, south east of Iran. Scientific Reports. 2021 May 24;11(1):10786.
  14. Federation I. The IDF consensus worldwide definitionofthemetabolicsyndrome. 2014 r03r26]. http://www. idf. org/webdata/ocs/meta_ syndrome definition. pdf.
  15. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. Journal of the American College of Cardiology. 2010 Sep 28;56(14):1113-32.
  16. Ju SY, Lee JY, Kim DH. Association of metabolic syndrome and its components with all-cause and cardiovascular mortality in the elderly: a meta-analysis of prospective cohort studies. Medicine. 2017 Nov 1;96(45):e8491.
  17. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. The Lancet. 2008 Jun 7;371(9628):1927-35.
  18. Akhondian J, Kiani MA, Jafari SA, Beiraghi Toosi M, Mirzaei Najm Abad M, Ahanchian H, et al. Evaluation of liver enzymes rising in patients treated with sodium valproate (VPA). International Journal of Pediatrics. 2015 Jun 1;3(3.2):685-9.
  19. Ramezankhani A, Azizi F, Hadaegh F, Eskandari F. Sex-specific clustering of metabolic risk factors and their association with incident cardiovascular diseases: a population-based prospective study. Atherosclerosis. 2017 Aug 1;263:249-56.
  20. Yousefzadeh G, Shokoohi M, Najafipour H, Shadkamfarokhi M. Applying the Framingham risk score for prediction of metabolic syndrome: the Kerman Coronary Artery Disease Risk Study, Iran. ARYA atherosclerosis. 2015 May;11(3):179.
  21. Sarrafzadegan N, Gharipour M, Sadeghi M, Nezafati P, Talaie M, Oveisgharan S, et al. Metabolic syndrome and the risk of ischemic stroke. Journal of Stroke and Cerebrovascular Diseases. 2017 Feb 1;26(2):286-94.
  22. Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SM, Heidari-Bakavoli AR, et al. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. International journal of public health. 2015 Jul;60:561-72.
  23. Asadi Z, Shafiee M, Sadabadi F, Heidari‐Bakavoli A, Moohebati M, Khorrami MS, et al. Association of dietary patterns and risk of cardiovascular disease events in the MASHAD cohort study. Journal of Human Nutrition and Dietetics. 2019 Dec;32(6):789-801.
  24. 24. Huang PL. A comprehensive definition for metabolic syndrome. Disease models & mechanisms. 2009 Apr 30;2(5-6):231-7.
  25. James WP, Schofield EC. Human energy requirements. A manual for planners and nutritionists. 1990 Dec 29.
  26. Giugliano D, Esposito K. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. Diabetes care. 2006 Jan 1;29(1):175-6.
  27. Yang W, Guo S, Wang H, Li Y, Zhang X, Hu Y, et al. The Association of Metabolic Syndrome with the development of cardiovascular disease among Kazakhs in remote rural areas of Xinjiang, China: a cohort study. BMC Public Health. 2021 Dec;21:1-8.
  28. Gustavo de Sousa Barbalho Y, Morato Stival M, Ramos de Lima L, Cristina Rodrigues da Silva I, de Oliveira Silva A, Vieira Gomes da Costa M, et al. Impact of metabolic syndrome components in high-risk cardiovascular disease development in older adults. Clinical Interventions in Aging. 2020 Sep 18:1691-700.
  29. Mazloomzadeh S, Zarandi FK, Shoghli A, Dinmohammadi H. Metabolic syndrome, its components and mortality: A population-based study. Medical journal of the Islamic Republic of Iran. 2019 Feb 27;33:11.
  30. Mozaffary A, Bozorgmanesh M, Sheikholeslami F, Azizi F, Eskandari F, Hadaegh F. Added value of different metabolic syndrome definitions for predicting cardiovascular disease and mortality events among elderly population: Tehran Lipid and Glucose Study. European journal of clinical nutrition. 2014 Jul;68(7):853-8.
  31. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes care. 2004 Nov 1;27(11):2689-94.
  32. Isomaa BO, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes care. 2001 Apr 1;24(4):683-9.
  33. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes care. 2003 Apr 1;26(4):1251-7.
  34. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama. 2002 Dec 4;288(21):2709-16.
  35. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program–Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes care. 2007 Jan 1;30(1):8-13.
  36. Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. Sex-and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacological research. 2017 Jun 1;120:34-42.
  37. Onat A, Ceyhan K, Başar Ö, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels —a    prospective      and     cross-sectional evaluation. Atherosclerosis. 2002 Dec 1;165(2):285-92.
  38. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San AntonioHeart Study. Circulation. 2004 Sep 7;110(10):1251-7.
  39. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic value of the metabolic syndrome in essential hypertension. Journal of the American College of Cardiology. 2004 May 19;43(10):1817-22.
  40. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes care. 2005 Feb 1;28(2):385-90.
  41. Hari P, Nerusu K, Veeranna V, Sudhakar R, Zalawadiya S, Ramesh K, et al. A gender-stratified comparative analysis of various definitions of metabolic syndrome and cardiovascular risk in a multiethnic US population. Metabolic syndrome and related disorders. 2012 Feb 1;10(1):47-55.
  42. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005 Aug 2;112(5):666-73.
  43. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. The Canadian journal of cardiology. 1988 Jul 1;4:5A-10A.
  44. Njelekela MA, Mpembeni R, Muhihi A, Mligiliche NL, Spiegelman D, Hertzmark E, et al. Gender-related differences in the prevalence of cardiovascular disease risk factors and their correlates in urban Tanzania. BMC cardiovascular disorders. 2009 Dec;9:1-8.
  45. Sader MA, Celermajer DS. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovascular research. 2002 Feb 15;53(3):597-604.
  46. DeVon HA, Ryan CJ, Ochs AL, Shapiro M. Symptoms across the continuum of acute coronary syndromes: differences between women and men. American journal of critical care. 2008 Jan 1;17(1):14-24.
  47. Kokubo Y, Okamura T, Yoshimasa Y, Miyamoto Y, Kawanishi K, Kotani Y, et al. Impact of metabolic syndrome components on the incidence of cardiovascular disease in a general urban Japanese population: the Suita study. Hypertension Research. 2008 Nov;31(11):2027-35.
  48. Noto D, Barbagallo CM, Cefalù AB, Falletta A, Sapienza M, Cavera G, et al. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. Atherosclerosis. 2008 Mar 1;197(1):147-53.
  49. Kim I, Kim MC, Sim DS, Hong YJ, Kim JH, Jeong MH, et al. Effect of the metabolic syndrome on outcomes in patients aged< 50 years versus> 50 years with acute myocardial infarction. The American Journal of Cardiology. 2018 Jul 15;122(2):192-8.
  50. Lee SH, Tao S, Kim HS. The prevalence of metabolic syndrome and its related risk complications among Koreans. Nutrients. 2019 Jul 30;11(8):1755.
  51. Johans CE, Bajic P, Kirshenbaum E, Blackwell RH, Kothari AN, Kuo PC, et al. Metabolic syndrome increases risk of postoperative myocardial infarction following percutaneous nephrolithotomy. Journal of Endourology. 2018 Nov 1;32(11):1039-43..
  52. Lovic MB, Djordjevic DB, Tasic IS, Nedeljkovic IP. Impact of metabolic syndrome on clinical severity and long-term prognosis in patients with myocardial infarction with ST-segment elevation. Hellenic journal of cardiology. 2018 Jul 1;59(4):226-31.
  53. Mente A, Yusuf S, Islam S, McQueen MJ, Tanomsup S, Onen CL, et al. Metabolic syndrome and risk of acute myocardial infarction: a case-control study of 26,903 subjects from 52 countries. Journal of the American College of Cardiology. 2010 May 25;55(21):2390-8.
Journal of Cardio-Thoracic Medicine
Volume 13, Issue 1
March 2025
Pages 1462-1475

Files

Share

How to cite

Statistics